Tim Meyer

17PUBLICATIONS
100CO-AUTHORS
Solid tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 04, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.

|Feb 28, 2025
Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials.

Bill Byrom, Anthony Everhart, Paul Cordero

|Jan 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.

Shailender Bhatia, Suzanne L Topalian, William Sharfman

|Dec 05, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Daniel H Palmer, Richard Jackson, Christoph Springfeld

|Apr 16, 2024
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.

Abid Suddle, Helen Reeves, Richard Hubner

|Dec 11, 2022
New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations.

Julien Edeline, Tim Meyer, Jean-Frédéric Blanc

Pageof 3

Frequent Collaborators

2 joint publications

Kai-Wen Huang

2 joint publications

Pinelopi Andrikakou

2 joint publications

Cheng Ean Chee

2 joint publications

Robert Habib